Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
MedCity NewsTopic alignment 85
Argenx’s Unnatural Products acquisition brings a macrocyclic peptides discovery platform for developing oral peptide drugs. The deal brings a new modality to Argenx, whose immunology R&D had focused on antibodies.
Filed under
- Market structure & M&Amatch 85
Bon Secours Hikes Bid After Surgery Partners Gets Competing Offer
Ambulatory Surgery Center NewsTopic alignment 95
12% of U.S. hospitals are owned by private equity
Healthcare DiveTopic alignment 92
Labcorp completes $375M Millennium Health takeover
MedTech DiveTopic alignment 88
LiveWell Partners Expands Michigan Footprint With Assured Home Health and Hospice Acquisition
Hospice NewsTopic alignment 85